Pregnane X receptor (PXR) is a ligand-dependent transcription factor that plays an important role in xenobiotic/drug metabolism. The ligand-receptor interaction transcriptionally activates phase I and phase II enzymes, and membrane-bound transporters in a coordinated manner and ultimately leads to detoxification and excretion of the ligands. One of the direct target genes is cytochrome P450 3A4 (CYP3A4) which is responsible for metabolism of over 50% of clinically used drugs. Understanding the regulation of PXR is important for treatment of disease and avoidance of untoward drug-drug interactions. In this research, we have used various biochemical and molecular approaches to investigate factors that regulate the transcriptional activity of PXR. We have stably transfected PXR into HepG2 human liver hepatoma cells. Using these PXR-HepG2 cells, we surveyed the histone methyltransferases that interact with PXR. Based on results from co-immunoprecipitation/methyltransferase, N-terminal peptide sequencing, GST-pulldown assays, we found that protein arginine methyltransferase 1 (PRMT1) is a predominant histone methyltransferase in HepG2 cells. Evidence from other laboratories suggests that histone methylation by PRMT1 sets the stage for subsequent histone modifications such as the acetylation of histone H4. These modifications are believed to be important for transcriptional and epigenetic regulation of gene expression. We hypothesize that PRMT1 plays a role in the epigenetic changes regulated by PXR. PRMT1-dependent histone methylation changes may be involved in epigenetic cell memory where prior exposure to certain agents may alter the chromatin (or priming the chromatin) with a "primed" state which alters the subsequent magnitude or duration of gene expression. In our study, we have found that pretreatment of PXR-HepG2 cells with DMSO greatly enhanced PXR-mediated activation of CYP3A4 upon rifampicin treatment. DMSO pretreatment altered histone modifications association with the promoter of the PXR-regulated gene (CYP3A4). Inhibition of histone methylation by PRMT1 either through RNAi or the methyltransferase inhibitor (Adox) abolished the priming effects. My research results strongly indicate that PRMT1 is involved in transcriptional regulation of PXR and may be involved in epigenetic memory of liver cells where prior exposure to agents changes the subsequent detoxification responses.

To understand the mechanisms of transcriptional regulation of PXR, we performed yeast two-hybrid screenings to search for PXR-interacting proteins in a human liver cDNA library using the PXR ligand binding domain as the bait. More than one million independent clones were screened. One positive clone was a partial cDNA of CNOT2 (amino acid 183-540). CNOT2 is a component of CCR4-NOT that is a multi-subunit protein complex highly conserved from yeast to humans. Using a mammalian two-hybrid system in CV-1 cells and GST-pull down assays, we confirmed the direct interaction between PXR and CNOT2 and mapped the specific domains of association. In HepG2 cells, over expression of CNOT2 suppressed the PXR-regulated luciferase reporter gene activity. siRNA knockdown of CNOT2 potentiated PXR-transcriptional activity. These results strongly suggest that the CCR4-NOT complex is significantly involved in transcriptional regulation of PXR. The immuno-precipitated CNOT2 complex contained deadenylase activity as determined by an in vitro RNA decay assay. The presence of transfected PXR inhibited the cNOT2-associated deadenylase activity, as demonstrated by poly(A) tail PCR. Cellular localization of PXR and cNOT2 by immuno-fluorescence microscopy indicates that the interaction might occur within Cajal Bodies. Taken together, these results suggest that PXR regulates the mRNA turnover through direct interaction with the NOT2 component of the CCR4-NOT complex. PXR is also involved in colon cancer progression. Our results indicate that the evolutionarily conserved PXR protects organisms from carcinogenesis by inhibiting tumor growth as well as eliminating carcinogenic substances. Our laboratory proposes that pregnane X receptor has an important role in maintaining the balance of cells progressing through the cell cycle. In vitro and in vivo experiments demonstrate expression of PXR in colon cancer cells slows the progression of tumor formation. Colony growth of the PXR-transfected HT29 cells was suppressed in soft agar assay. In the xenograft assay, the tumor size formed in nude mice was significantly suppressed in HT29 cells stably transfected with PXR (310 mg /- 6.2 vs. 120 mg±6, p<0.01). The number of Ki-67 positive cells were significantly decreased in PXR-transfected HT29 xenograft tumor tissue compared vector-transfected HT29 controls (p<0.01) as determined by immuno-histochemistry suggesting that PXR inhibits proliferation of colon cancer cells. Results of flow cytometry analysis indicated that PXR-transfection in HT29 cells caused G0/G1 arrest. The growth inhibitory effects of PXR are likely mediated through the E2F/Rb-regulated check point since E2F1 nuclear expression was significantly inhibited by PXR over expression.

Polycyclic aromatic hydrocarbons (PAHs) are widely distributed in the environment and are generated by many sources. Though the potential of PAH-rich mixtures to cause health effects has been known for almost a century, there are still unanswered questions about the levels of PAHs in the environment, the potential for human exposure to PAHs, the health effects associated with exposure, and how genetic susceptibility influences the extent of health effects in individuals. The first objective of this research was to quantify concentrations of PAHs in samples of settled house dust collected from homes in Azerbaijan, China, and Texas. The trends of PAH surface loadings and percentage of carcinogenic PAHs were China > Azerbaijan > Texas, indicating that the risk of health effects from exposure to PAHs in house dust is highest in the Chinese population and lowest in the Texas population. PAHs in China and Azerbaijan were derived mainly from combustion sources; Texas PAHs were derived from unburned fossil fuels such as petroleum. The second objective of this research was to investigate the effect of pregnane X receptor (PXR) on the genotoxicity of benzo[a]pyrene (BaP). BaP treatment resulted in significantly lower DNA adduct levels in PXR-transfected HepG2 cells than in parental HepG2 cells. Total GST enzymatic activity and mRNA levels of several metabolizing enyzmes were significantly higher in cells overexpressing PXR. These results suggest that PXR protects cells against DNA damage by PAHs such as BaP, possibly through a coordinated regulation of genes involved in xenobiotic metabolism. The third objective of this research was to investigate biomarkers of exposure in house mice (Mus musculus) exposed to PAH mixtures in situ. Mice and soil were collected near homes in Sumgayit and Khizi, Azerbaijan. Mean liver adduct levels were significantly higher in Khizi than in Sumgayit. Mean lung and kidney adduct levels were similar in the two regions. The DNA lesions detected may be a combination of environmentally-induced DNA adducts and naturally-occurring I-compounds. PAHs were present at background levels in soils from both Khizi and Sumgayit. It appears that health risks posed to rodents by soil-borne PAHs are low in these two areas.

Mémoire numérisé par la Direction des bibliothèques de l'Université de Montréal.

No description available.

Nahrungsinhaltsstoffe sind im Organismus an Steuerungsprozessen und Stoffwechselvorgängen beteiligt, wobei die Mechanismen ihrer Wirkung noch nicht völlig aufgeklärt sind. Wie Vitamin E zeigen auch sekundäre Pflanzeninhaltsstoffe in Zellsystemen sowie <I>in vivo</I> eine Reihe biologischer Wirkungen, deren Erklärung jedoch häufig auf ihre antioxidative Eigenschaft reduziert wird. Ziel der Dissertation war es, den Einfluss von Vitamin E und anderen Pflanzeninhaltsstoffen (in Form von Pflanzenextrakten oder isolierten sekundären Pflanzeninhaltsstoffen, z.B. Polyphenole), die bisher alle hauptsächlich als Antioxidanz klassifiziert wurden, auf die transkriptionelle Regulation von Phase I- und Phase II-Enzymen zu untersuchen. Dazu wurde die Aktivierung des PXR (pregnane X receptor) und des Nrf2 (NF-E2-related factor-2) als zentrale Transkriptionsfaktoren der Phase I- bzw. Phase II-Enzyme getestet. <br><br> Der Einfluss von verschiedenen Vitamin E-Formen und antioxidativen Pflanzeninhaltsstoffen in Form von Reinsubstanzen (Curcumin, EGCG, Medox, Quercetin, Resveratrol und Sulforaphan) oder Pflanzenextrakten (aus Blaubeeren, Gewürznelken, Himbeeren, Nelkenpfeffer, Thymian oder Walnüssen) auf die Aktivierung von PXR und Nrf2 sowie des Promotors eines jeweiligen Zielgens (CYP3A4 bzw. GI-GPx) wurde <I>in vitro</I> mit Reportergenplasmiden untersucht. Es zeigte sich, dass sowohl Vitamin E-Formen als auch verschiedene sekundäre Pflanzeninhaltsstoffe PXR und/oder Nrf2 sowie die Promotoren der jeweiligen Zielgene CYP3A4 bzw. GI-GPx aktivieren. In einem Tierexperiment konnte diese genregulatorische Wirkung von Vitamin E auf die <I>in vivo</I>-Situation übertragen werden. In Lebern von Mäusen, deren Futter unterschiedliche Mengen von Vitamin E enthielt (Mangel-, Normal- und Überflussdiät), wurde eine direkte Korrelation zwischen der alpha-Tocopherol-Konzentration und der Cyp3a11 mRNA-Expression nachgewiesen (Cyp3a11 ist das murine Homolog zum humanen CYP3A4). Entgegen der <I>in vitro</I>-Situation hatte gamma-Tocotrienol <I>in vivo</I> einen nur kaum nachweisbaren Effekt auf die Expression der Cyp3a11 mRNA, induzierte aber die Expression der alpha-TTP mRNA. Es konnte gezeigt werden, dass Vitamin E und sekundäre Pflanzeninhaltsstoffe Phase I- und Phase II-Enzyme transkriptionell regulieren können. <br><br> Die Wirkungen des Vitamin E können sich allerdings nur entfalten, wenn die Vitamin E-Formen ausreichend vom Körper aufgenommen werden. Gegenstand der Dissertation waren daher auch Untersuchungen zur Bioverfügbarkeit (zelluläre Akkumulation und Metabolismus) verschiedener Vitamin E-Formen. Es konnte gezeigt werden, dass Unterschiede in der chemischen Struktur der Vitamin E-Formen deren zelluläre Akkumulation und Metabolisierung beeinflussen. <br><br> Unter Berücksichtigung der Ergebnisse der Dissertation lassen sich protektive Wirkungen von antioxidativen Nahrungsinhaltsstoffen auch unabhängig von ihren antioxidativen Eigenschaften über die Induktion zelleigener Schutzsysteme, einschließlich der Phase I- und Phase II-Enzyme, erklären. Die Induktion der zelleigenen Abwehr lässt sich auch als adaptive Antwort (sog. "adaptive response") des Organismus gegenüber zellschädigenden Ereignissen betrachten. / In the organism food compounds are involved in regulatory and metabolic processes although the mechanisms of their effects have not been completely elucidated yet. Like vitamin E, secondary plant compounds have diverse biological effects, both in cell systems as well as <I>in vivo</I>. However, the explanation thereof is often reduced to their antioxidative capacity. The aim of this thesis was to investigate the influence of vitamin E and other plant compounds (in form of plant extracts or isolated secondary plant compounds, e.g. polyphenols), which were up to now classified primarily as antioxidants, on the transcription of phase I- and phase II-enzymes. For this, the activation of central transcription factors of the phase I- or phase II enzymes, PXR (pregnane X receptor) and Nrf2 (NF-E2-related factor-2), was tested. <br><br> The influence of different vitamin E forms and antioxidative plant compounds in form of pure substances (curcumin, EGCG, Medox, quercetin, resveratrol, and sulforaphane) or plant extracts (from blueberries, clove, raspberries, allspice, thyme, or walnuts) on the activation of PXR and Nrf2 as well as on the promoter of a respective target gene (CYP3A4 or GI-GPx) was investigated <I>in vitro</I> by reporter gene assays. It appeared that vitamin E forms as well as different secondary plant compounds activate PXR and/or Nrf2 as well as the promoter of the respective target genes CYP3A4 and GI-GPx. The effects of vitamin E were confirmed <I>in vivo</I> by an animal experiment. In livers of mice whose diet contained different amounts of vitamin E (deficient, adequate and supra-nutritional), a direct correlation between alpha-tocopherol content and Cyp3a11 mRNA expression was shown (Cyp3a11 is the murine homolog to the human CYP3A4). In contrast to the <I>in vitro</I> observations, gamma-tocotrienol <I>in vivo</I> only had a small effect on the expression of Cyp3a11 mRNA. However, it induced the expression of alpha-TTP on mRNA level. It could be shown that vitamin E and secondary plant compounds can influence the transcriptional regulation of phase I- and/or phase II-enzymes. <br><br> However, these effects of vitamin E can only be seen if the vitamin E forms are taken up by the body sufficiently. Therefore, another aim of the thesis was to investigate the bioavailability of different vitamin E forms (i.e., cellular accumulation and metabolism). It could be shown that differences in the chemical structure of vitamin E forms influence their cellular accumulation and metabolism. <br><br> Regarding the results of this thesis, protective effects of antioxidative food compounds can be explained independent of their antioxidative properties by the induction of cellular protective systems, including phase I- and phase II-enzymes. The induction of cellular defence mechanism can also be considered as an adaptive response of the organism towards cell-damaging events.

De plus en plus d’inhibiteurs de kinase (IKs) sont testés dans le cancer de la prostate qui représente chez l’homme un enjeu de santé publique majeur de par son incidence (1er cancer) et sa mortalité (4ème cancer). Les essais cliniques pour évaluer l'efficacité des IKs dans cette indication ont donné des résultats mitigés malgré la présence de leurs cibles pharmacologiques dans les tumeurs de prostate (VEGF, EGFR, CMET..), pouvant faire penser que l’inefficacité serait en partie liée à la molécule elle-même et à sa pharmacocinétique/pharmacodynamie. En effet, les IKs sont sujets à un métabolisme et un transport intense via des enzymes de phase I et II et des transporteurs contrôlés pour la majorité par le récepteur nucléaire PXR (Pregnane X Receptor, gène NR1I2). En plus d’être abondamment exprimé dans le foie et le long du tractus gastro-intestinal, PXR est également exprimé dans certaines tumeurs épithéliales et pourrait être impliqué dans la résistance aux chimiothérapies par augmentation du catabolisme et de l’efflux de ces agents anticancéreux. A ce jour une seule étude a révélé l’expression de PXR dans le cancer de la prostate sans en avoir évalué l’impact sur la réponse aux traitements utilisés dans cette indication. En collaboration avec le Pr G. Fromont, nous avons observé dans une cohorte de 449 patients que l’expression de PXR était plus fréquemment retrouvée dans les cancers résistants à la castration et les métastases, par rapport aux cancers cliniquement localisés dans lesquels l’expression de PXR était corrélée avec le stade TNM et le score ISUP. Ces résultats confirment donc l’intérêt d’étudier le rôle que peut jouer PXR et les gènes du métabolisme et du transport qu’il régule, dans la sensibilité aux IKs dans les cancers de la prostate.Nous avons mesuré l’expression de PXR et de ses gènes cibles dans les lignées de cancer de la prostate 22RV1, LnCap, PC3 et DU145. Les résultats montrent une expression significative des enzymes et transporteurs responsables de la détoxication des IKs mais une faible expression de PXR liée à des phénomènes d’hyperméthylation NR1I2 dans nos lignées Cela nous a conduit à établir des modèles de surexpression stable de PXR dans lesquels l’agoniste SR12813 est capable d’induire l’activité transcriptionnelle de ce xénorécepteur, indiquant la compétence métabolique de ces lignées. À l'aide de ces modèles, nous avons démontré que la surexpression de PXR module la réponse à l’erlotinib, le dasatinib, le dabrafénib et l’afatinib démontrant que PXR joue un rôle fonctionnel dans la sensibilité à ces IKs. Nous avons également démontré que certains inhibiteurs avaient des propriétés agonistes de PXR, notamment le dabrafénib qui montre un effet agoniste plus marqué que le composé de référence SR12813, ce qui n’a jamais été démontré. Cette découverte originale nous a conduit à engager une collaboration pour tenter de cristalliser le complexe PXR/dabrafénib et à tester l’hypothèse que l’induction de l’activité PXR pouvait entraîner une modification du métabolisme et/ou du transport d’autres médicaments co-administrés. Or, nous avons observé dans la lignée 22RV1 un effet additif entre le dabrafénib et le tramétinib, une combinaison approuvée dans le traitement du mélanome, qui devient antagoniste lorsque PXR est surexprimé, résultat qui va effectivement dans le sens de notre hypothèse même s’il reste à démontrer que cet effet est bien lié à une altération du métabolisme de ces IKs, ce que nous sommes en train d’évaluer en dosant les métabolites de ces IKs. L’ensemble de nos données pourraient servir de rationnel biologique dans le choix des IKs ou de leurs combinaisons à tester avec les hormonothérapies et chimiothérapies déjà utilisés dans le traitement du cancer de la prostate, afin de potentialiser la réponse tumorale. / More and more kinase inhibitors (KIs) are tested in prostate cancer that represents a major health issue in men with its incidence and mortality rates. Clinical trials to evaluate KIs efficacy in prostate cancer gave disapointing results depsite the presence of KIs pharmacological targets in prostate tumors (VEGF, EGFR, CMET..), suggesting that inefficiency of these drugs would be at least in part linked to the inhibitor itself or its pharmacodynamics/pharmacokinetics parameters. Indeed KIs are metabolized and transported via phase I and II enzymes that are mainly controlled by the xenoreceptor PXR (Pregnane X Receptor, gène NR1I2). It is mainly expressed in liver and gastro-intestinal tract but also in epithelial tumors. PXR is also involved in the resistance to chemotherapies by increasing the catabolism and the efflux of these anticancer agents. To date only one study evaluated PXR expression in prostate cancer without evaluating its impact on treatment efficacy. In collaboration with Pr G. Fromont we analyzed a cohort of 449 prostate tumors and observed that PXR was more frequently detected in castration resistant or metastatic tumors as compared to clinically localized forms in which PXR expression was significantly correlated with TNM and ISUP Score. These results confirmed the interest to study the potential role of PXR and its target genes in the sensitivity to kinase inhibitors in prostate cancer models.We measured the expression of PXR and its target genes in prostate cancer cell lines 22RV1, LnCap, PC3 and DU145. The results showed that enzymes and transporters involved in KI detoxification was significantly expressed in these cells whereasPXR was poorly expressed due to hypermethylation of NR1I2 in our cells. This lead us to develop specific prostate cancer cell models stably overexpressing PXR in which transcriptional activity of PXR can be induced by its known agonist SR12813 further indicating that prostate cancer cells are metabolically competent. Using these models we showed that PXR overexpression modulates the sensitivity of 22RV1 cells to erlotinib, dasatinib, dabrafenib and afatinib, demonstrating that PXR plays a functional role in the sensitivity to KIs. We also demonstrated that several KIs were PXR agonists, including dabrafenib that displayed enhanced agonistic properties as compared to SR12813, a result that was never published before. This original finding led us to engage the cristalization of PXR/dabrafenib complex and to test whether induction of PXR could lead to an alteration of metabolism and transport of other drugs that are co-administered. In this line we have observed that in 22RV1 cells the additive effect of the combination of dabrafenib with trametinib that is already approved in the treatment of melanomas, became antagonistic when PXR was overexpressed in these cells. This result is supporting our hypothesis though we still need to demonstrate that this effect is linked to a change in drugs metabolism, which is currently under investigation by the measurement of the known metabolites of these KIs.Altogether, our data could serve as rational basis for the choice of kinase inhibitors or their potential combinations that could be tested in further clinical trials alone or in association with hormone therapies or with chemotherapies that are currently prescribed in the treatment of advanced prostate cancers, in order to potentiate tumor response.

Fish may be exposed to an array of pharmaceuticals that are discharged into the aquatic environment, paralleling advances in medical knowledge, research and technology. Pharmaceuticals by their nature are designed to target specific receptors, transporters, or enzymes. Nuclear receptors (NRs) are often a key component of the therapeutic mechanism at play, and many of these are conserved among vertebrates. Consequently, fish may be affected by environmental pharmaceutical exposure, however there has been relatively little characterisation of NRs in fish compared with in mammals. In this thesis common carp (C. carpio) were exposed to selected pharmaceuticals in vitro and in vivo to investigate effects centred on the pregnane X receptor (PXR) and peroxisome proliferator-activated receptor alpha (PPARα), two key NRs involved in organism responses to pharmaceutical exposure. The PXR acts as a xenosensor, modulating expression of a number of xenobiotic metabolising enzymes (XMEs) in mammals. In a primary carp hepatocyte model it was shown that expression of a number of XMEs was altered on exposure to rifampicin (RIF), as occurs in mammals. This response was repressed by addition of ketoconaozle (KET; PXR-antagonist), indicating possible PXR involvement. The genes analysed showed up-regulation on exposure to ibuprofen (IBU) and clofibric acid (CFA), but not clotrimazole (CTZ) or propranolol (PRP). The lack of response to mammalian PXR-agonist CTZ was unexpected. In contrast, the same XME genes were found to be up-regulated in vivo after 10 days of exposure of carp to CTZ, although this response occurred only for a relatively high exposure concentration. CTZ was found to concentrate in the plasma (with levels up to 40 times higher than the water). Development and application of a reporter gene assay to measure PXR activation in carp (cPXR) and human PXR showed CTZ activation of cPXR, supporting data from the in vivo studies. Furthermore, activation was seen at concentrations as low as 0.01 μM. Interestingly RIF did not induce a response in the cPXR reporter gene assay, contrasting with the hepatocyte culture work. Taken together, the data presented here suggests divergence in the PXR pathway between mammals and fish in terms of ligand activation and downstream gene targets. PPARα was investigated in carp in vivo using CFA as a mammalian PPARα-agonist. Overall the resulting data suggested a broadly similar role for this NR in lipid homeostasis in fish as for mammals, with a number of PPARα-associated genes and acyl-coA oxidase (ACOX1) activity up-regulated in response to CFA exposure. A number of XMEs were also up-regulated by CFA (in vivo and in vitro), potentially extending the role of PPARα in fish (carp) to regulation of xenobiotic metabolism. The work presented has provided further characterisation of PXR and PPARα in fish. Elucidation of these pathways is vital to provide meaningful data in terms of establishing toxicity and mechanism-of-action data for pharmaceuticals and other compounds in fish, to allow validation of read-across approaches and ultimately aid in their environmental risk assessment. In vitro approaches are attractive ethically, financially and can provide useful mechanistic characterisation of compounds and the primary hepatocyte model and reporter gene assays used here show potential for the screening of pharmaceutical compounds in fish. However, further understanding of the metabolism of drugs and chemicals in fish is required to establish the true value of these methods for informing on possible effects in fish, in vivo.

Charles University Faculty of Pharmacy in Hradec Králové Department of Pharmacology & Toxicology Student: Klára Dohnalová Supervisor: prof. PharmDr. Petr Pávek, Ph.D. Title of diploma thesis: Inhibitory effect of SPA70 on hPXR activation This work focuses on pregnane X receptor (PXR) and its antagonists. PXR is a ligand-activated nuclear receptor that plays a major role in detoxification of xenobiotics and protecting the organism from their toxic effects. Recent evidence also shows endogenous action of PXR in the metabolism of lipids, glucose and bile acids. However, PXR activation could be harmful, since induction of biotransformation enzymes by PXR agonists may result in reduced treatment efficacy, increased toxicity of drug metabolites and resistance to chemotherapeutic agents. Recent research has been intensively focused on PXR antagonists capable of abolishing these unfavourable effects. Recently discovered human PXR antagonist SPA70 has a promising potential for future usage. In this study, we investigated the inhibitory effect of SPA70 on activated PXR. To activate PXR we used agonists binding directly to PXR (rifampicin, hyperforin, SR12813) and also agonists activating PXR indirectly via cell signalling pathways (U0126, PD184352, PD0325901). Experiments were performed using luciferase...

For more than 80 years vitamin E has been in the focus of scientific research. Most of the progress concerning non-antioxidant functions, nevertheless, has only arisen from publications during the last decade.<br> Most recently, the metabolic pathway of vitamin E has been almost completely elucidated. Vitamin E is metabolized by truncation of its side chain. The initial step of an omega-hydroxylation is carried out by cytochromes P450 (CYPs). This was evidenced by the inhibition of the metabolism of alpha-tocopherol by ketoconozole, an inhibitor of CYP3A expression, whereas rifampicin, an inducer of CYP3A expression increased the metabolism of alpha-tocopherol. Although the degradation pathway is identical for all tocopherols and tocotrienols, there is a marked difference in the amount of the release of metabolites from the individual vitamin E forms in cell culture as well as in experimental animals and in humans. Recent findings not only proposed an CYP3A4-mediated degradation of vitamin E but also suggested an induction of the metabolizing enzymes by vitamin E itself.<br> In order to investigate how vitamin E is able to influence the expression of metabolizing enzymes like CYP3A4, a pregnane X receptor (PXR)-based reporter gene assay was chosen. PXR is a nuclear receptor which regulates the transcription of genes, e.g., CYP3A4, by binding to specific DNA response elements. And indeed, as shown here, vitamin E is able to influence the expression of CYP3A via PXR in an in vitro reporter gene assay. Tocotrienols showed the highest activity followed by delta- and alpha-tocopherol. An up-regulation of Cyp3a11 mRNA, the murine homolog of the human CYP3A4, could also be confirmed in an animal experiment. The PXR-mediated change in gene expression displayed the first evidence of a direct transcriptional activity of vitamin E. PXR regulates the expression of genes involved in xenobiotic detoxification, including oxidation, conjugation, and transport. CYP3A, e.g., is involved in the oxidative metabolism of numerous currently used drugs. This opens a discussion of possible side effects of vitamin E, but the extent to which supranutritional doses of vitamin E modulate these pathways in humans has yet to be determined. <br><br> Additionally, as there is arising evidence that vitamin E's essentiality is more likely to be based on gene regulation than on antioxidant functions, it appeared necessary to further investigate the ability of vitamin E to influence gene expression. Mice were divided in three groups with diets (i) deficient in alpha-tocopherol, (ii) adequate in alpha-tocopherol supply and (iii) with a supranutritional dosage of alpha-tocopherol. After three months, half of each group was supplemented via a gastric tube with a supranutritional dosage of gamma-tocotrienol per day for 7 days. Livers were analyzed for vitamin E content and liver RNA was prepared for hybridization using cDNA array and oligonucleotide array technology. A significant change in gene expression was observed by alpha-tocopherol but not by gamma-tocotrienol and only using the oligonucleotide array but not using the cDNA array. The latter effect is most probably due to the limited number of genes represented on a cDNA array, the lacking gamma-tocotrienol effect is obviously caused by a rapid degradation, which might prevent bioefficacy of gamma-tocotrienol.<br> Alpha-tocopherol changed the expression of various genes. The most striking observation was an up-regulation of genes, which code for proteins involved in synaptic transmitter release and calcium signal transduction. Synapsin, synaptotagmin, synaptophysin, synaptobrevin, RAB3A, complexin 1, Snap25, ionotropic glutamate receptors (alpha 2 and zeta 1) were shown to be up-regulated in the supranutritional group compared to the deficient group. The up-regulation of synaptic genes shown in this work are not only supported by the strong concentration of genes which all are involved in the process of vesicular transport of neurotransmitters, but were also confirmed by a recent publication. However, a confirmation by real time PCR in neuronal tissue like brain is now required to explain the effect of vitamin E on neurological functionality. The change in expression of genes coding for synaptic proteins by vitamin E is of principal interest thus far, since the only human disease directly originating from an inadequate vitamin E status is ataxia with isolated vitamin E deficiency. Therefore, with the results of this work, an explanation for the observed neurological symptoms associated with vitamin E deficiency can be presented for the first time. / Chemisch handelt es sich bei Vitamin E um acht lipophile Derivate des 6 Chromanols mit einer Seitenkette. Nach dem Sättigungsgrad der Seitenkette lassen sich die Derivate in die Tocopherole (gesättigte Seitenkette) und die Tocotrienole (ungesättigte Seitenkette mit drei Doppelbindungen) einteilen. Entsprechend der Methylierung des Chromanrings lassen sie sich in alpha-, beta-, gamma- und delta-Tocopherol, bzw. Tocotrienol unterscheiden. Davon besitzt alpha-Tocopherol, das gleichzeitig die im Plasma dominierende Form darstellt, die höchste biologische Aktivität. Aufnahme wie auch der Transport von Vitamin E im Körper sind vergleichsweise gut erforscht. Die Kenntnisse zu Metabolismus und Elimination waren jedoch bis vor kurzem sehr lückenhaft. Lange Zeit waren nur Vitamin E-Metabolite mit geöffnetem Chromanring, die sogenannten Simon-Metabolite Tocopheronsäure und Tocopheronolacton bekannt. Diese Metabolite können nur aus oxidativ gespaltenem Vitamin E entstehen und galten daher auch als Beweis für die antioxidative Wirkung von Vitamin E. Mit verbesserter Analytik wurde vor einigen Jahren gezeigt, dass die Simon-Metabolite größtenteils Isolierungsartefakte sind. Stattdessen wurden Metabolite mit intaktem Chromanring identifiziert. Tocopherole wie auch Tocotrienole werden im Körper durch eine Verkürzung der Seitenkette abgebaut. Die Endprodukte sind in jedem Fall CEHCs (Carboxyethyl Hydroxychromane). Die Seitenkettenverkürzung startet mit einer omega-Hydroxylierung gefolgt von 5 Schritten &#61472;beta-Oxidation. Die omega Hydroxylierung der Seitenkette durch Cytochrom P450 (CYP) Enzyme wurde indirekt bestätigt. CYP3A4 gilt dabei als eines der wahrscheinlichsten Enzyme im Abbau von Vitamin E, die Beteiligung weiterer CYPs wird jedoch gleichfalls angenommen. Auffällig ist, dass nicht alle Vitamin E-Formen in gleichem Ausmaß abgebaut werden. Die Ausscheidung von CEHCs aus alpha-Tocopherol ist, verglichen zu andern Vitamin E-Formen, in kultivierten Zellen wie auch in vivo sehr gering. Die Art der Seitenkettenverkürzung von Vitamin E spricht für einen Abbau über das Fremdstoff-metabolisierende System, welches auch eine Vielzahl von Medikamenten verstoffwechselt.<br> Im ersten Teil der vorliegenden Arbeit konnte mittels Reportergenassay in HepG2 Zellen gezeigt werden, dass Vitamin E einen nukleären Rezeptor, den Pregnan X Rezeptor (PXR), zu aktivieren und die Expression von PXR-regulierten Genen zu beeinflussen vermag. PXR reguliert eine Reihe von Genen für Fremdstoff-metabolisierende Enzyme wie z.B. Cytochrom P450 3A4 durch Bindung an sein responsives Element im Promotor der Zielgene. Die untersuchten Vitamin E-Formen unterschieden sich deutlich hinsichtlich ihrer PXR-Aktivierung. Die Tocotrienole zeigten die höchste PXR-Aktivierung - vergleichbar mit Rifampicin, einem bekannt guten PXR-Aktivator - gefolgt von delta / alpha- und gamma-Tocopherol. Im Tierversuch an Mäusen konnte die erhöhte Expression von Cyp3a11, dem Homolog des humanen CYP3A4 in Abhängigkeit von der alpha-Tocopherol-Zufuhr bestätigt werden. Somit konnte erstmals gezeigt werden, dass Vitamin E die Expression von Genen direkt beeinflussen kann. Darüber hinaus unterstreicht diese Beobachtung die Möglichkeit einer Wechselwirkung von pharmakologischen Dosen Vitamin E mit dem Abbau von Medikamenten. Eine genregulatorische Funktion von Vitamin E ist auf den ersten Blick überraschend. Denn wenngleich Vitamin E vor über 80 Jahren als Fertilitätsfaktor bei Ratten entdeckt wurde, steht die erst später beschriebene antioxidative Eigenschaft von Vitamin E bis heute im Fokus der meisten Publikationen. Die molekularen Mechanismen der Essentialität von Vitamin E wurden dagegen wenig untersucht. Erst in den letzten Jahren finden Funktionen von Vitamin E Interesse, die über seine antioxidative Wirkung hinausgehen. Dabei konnte gezeigt werden, dass Vitamin E in vitro die Expression von Genen wie dem Scavenger Rezeptor CD36, dem Connective Tissue Growth Factor oder dem Peroxisomen-Proliferator aktivierten Rezeptor gamma beeinflussen kann.<br> Um weitere Zielgene von Vitamin E in vivo identifizieren zu können, wurden im zweiten Teil der vorliegenden Arbeit Mäuse in drei Fütterungsgruppen mit einer a) defizientem b) adäquatem sowie c) mit einer supranutritiven alpha Tocopherol-Versorgung über 3 Monate gefüttert. Zusätzlich erhielt die Hälfte der Tiere aus jeder Gruppe während der letzten Lebenswoche eine supranutritive Dosis gamma-Tocotrienol pro Tag. Aus den Lebern der Tiere wurde die RNA präpariert und die differentielle Genexpression mittels a) cDNA und b) Oligonukleotide enthaltenden GenChips analysiert.<br> Eine signifikante Änderung in der Genexpression zwischen den verschiedenen Fütterungsgruppen fand sich jedoch nur in den Analysen der Oligonukleotid GenChips. Dies kann auf die begrenzte Anzahl von Genen zurückzuführen sein, die auf den cDNA GenChips repräsentiert waren. Auch ein signifikanter Effekt von gamma-Tocotrienol auf die Genexpression konnte nicht beobachtet werden. Wahrscheinlich ist die hohe Ausscheidung von gamma-CEHC, dem Abbauprodukt von gamma-Tocotrienol, die im Urin der Tiere gemessen wurde und die damit womöglich verringerte Bioverfügbarkeit von gamma-Tocotrienol dafür verantwortlich.<br> Mit Hilfe der Oligonukleotid GenChips konnte jedoch ein signifikanter Effekt von alpha-Tocopherol auf die Expression einer Vielzahl von Genen beobachtet werden. Herausstechend war dabei die erhöhte Expression von für den vesikulären Transport essentiellen Genen, die für den synaptischen Signaltransfer benötigt werden. So wurden z.B. Synapsin, Synaptotagmin, Synaptophysin, Synaptobrevin, RAB3A, Complexin 1, Snap25, die ionotrophen Glutamat Rezeptoren alpha 2 und zeta 1 in Abhängigkeit von der alpha Tocopherol-Versorgung über die Diät erhöht exprimiert. Die Beobachtung, dass Vitamin E bei neurologischen Prozessen eine Rolle zu spielen scheint ist jedoch nicht neu. Bei Patienten mit einem Mangel an funktionellem alpha-Tocopherol-Transfer-Protein (alpha-TTP) kann es zu stark verringerten Plasmakonzentrationen an Vitamin E kommen, da alpha-TTP eine zentrale Rolle in der Aufnahme und Verteilung von Vitamin E im Körper einnimmt. An diesen Patienten können charakteristische Vitamin E-Mangelzustände beobachtet, die durch eine Reihe von neurologischen Störungen wie Ataxien, Hyporeflexie sowie eine verringerte propriozeptive und vibratorische Sensitivität gekennzeichnet sind. Mit den vorliegenden Ergebnissen kann nun erstmals eine mechanistische Erklärung für diese Symptome diskutiert werden. Eine Bestätigung der vorliegenden Ergebnisse via RT-PCR und Western Blot, z.B. in neuronalem Gewebe wie dem Gehirn, sowie anschließende funktionellen Untersuchungen ist daher dringend geboten.